Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegmolesatide - Jiangsu Hansoh Pharmaceutical

Next Previous
Drug Profile

Pegmolesatide - Jiangsu Hansoh Pharmaceutical

Alternative Names: EPO-018B; HS-20039; Pegol Sihematide - Jiangsu Hansoh Pharmaceutical; Pegsihematide - Jiangsu Hansoh Pharmaceutical; Peihuaxi hippocampal peptide - Jiangsu Hansoh Pharmaceutical; Saint Luolai

Latest Information Update: 09 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hansoh Pharmaceutical
  • Class Anti-inflammatories; Antianaemics; Peptides; Polyethylene glycols
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 05 Oct 2021 No development reported - Phase-II for Anaemia (Treatment-experienced) in China (IV) (Jiangsu Hansoh Pharmaceutical website, October 2021)
  • 15 May 2019 Phase-III clinical trials in Anaemia (Treatment-experienced) in China (SC) (NCT03902691)
  • 04 Apr 2019 Jiangsu Hansoh Pharmaceutical plans a phase III trial for Anaemia in patients with chronic kidney disease on dialysis in China in May 2019 (NCT03902691)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top